A Multi-Institutional Retrospective Study Suggests That Optimal Enteral Nutrition (EN) Influences Outcomes after Hematopoietic Stem Cell Transplantation in Children and Adults  by Dioguardi, Jackie et al.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S240eS265S248Results: The average increase among all patients receiving
Acrodose versus single donor platelets was 28.9 versus 19.8,
respectively. The median increase for Acrodose versus single
donor was 28 versus 16. The median time to next transfusion
for Acrodose versus single donor was 4 versus 2 days. In
subgroup analysis, the average increase among bonemarrow
transplant patients receiving Acrodose versus single donor
platelets was 21.7 versus 27.8, respectively. The median
increase for Acrodose versus single donor was 18 versus 20.
The median time to next transfusion for Acrodose versus
single donor was the same at 3 days. Among acute leukemia
patients, the average increase in patients receiving Acrodose
versus single donor platelets was 28 versus 18.6, respectively.
Themedian increase for Acrodose versus single donor was 27
versus 15. The median time to next transfusion for Acrodose
versus single donor was 4 versus 2 days.
Conclusion: In our single institutional experience, Acodose
platelets induced a more robust response and increased the
time to next transfusion compared to single donor platelets
among all patients and especially acute leukemia patients,
however this was not seen with the bone marrow transplant
patients. The reason for this is unclear andmore studies need
to be done.341
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Background: Human rhinovirus (HRV) is well known to
cause upper or lower respiratory tract infection (URTI/LRTI)
and is associated with increased morbidity and mortality in
immunocompromised adults such as those with cancer or
those undergoing hematopoietic stem cell transplantation
(HSCT). Asymptomatic children who are about to undergo
HSCT with a positive respiratory viral panel (RVP) pose a
special challenge and create a dilemma for providers when
deciding whether to move forward with HSCT in patients
with active viral disease.
Methods: We retrospectively reviewed the medical records
of all children who underwent HSCT from Jan 1, 2006 eMay
1, 2014 who had a RVP by PCR performed as part of the
pretransplant workup or within 180 days following HSCT.
Patients with rhinovirus identiﬁed pretransplant were not
treated with IVIG but received routine prophylaxis with IVIG.
Patients who developed rhinoviral infection were treated
with high dose IVIG. We reviewed data of all patients to
evaluate its impact on overall outcome. Demographic,
clinical, microbiologic, management, and outcome data were
collected.
Results: 50 pediatric HSCT patients were identiﬁed. A total of
23 patients were asymptomatic and identiﬁed on pretrans-
plant DFA screening. None of these patients developed
complications related to rhinovirus during the transplant. 21
patients were identiﬁed after HSCT was started due to
workup for fever or respiratory symptoms. None of these
children appeared to have signiﬁcant morbidity and
mortality related to rhinoviral infection. Of note,11/11 (100%)
umbilical cord recipients continued to have positive RVP and
viral shedding for several months following HSCT.Conclusions: Rhinovirus does not appear to have a negative
impact on the course of children undergoing HSCT.
The presence of rhinovirus is not a contraindication to
proceeding to transplant in children. Umbilical cord blood
transplant patients appeared to have delayed clearance of
the virus but this did not impact their clinical outcome.342
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Purpose: The objective of this studywas to compare the time
to engraftment of autologous hematopoietic stem cell
transplant (HSCT) patients who received ﬁlgrastim on day +5
versus day +10. In addition, number of febrile days, antibiotic
use, documented infection, and length of hospitalization
were compared. We hypothesized that duration of neu-
tropenia and incidence of neutropenic fever would be similar
in patients who received ﬁlgrastim on day +5 versus day +10.
Methods: Prior to initiation, the study received approval
from the Institutional Review Board. A HSCT database was
used to identify patients who have received autologous HSCT
from January 1, 2007 to June 30, 2013. Patients were included
if they received ﬁlgrastim on day +5 + 1 or day +10 + 1 post
HSCT. Patients werematched based on age + 5 years and type
of malignancy. The health-system’s electronicmedical record
system, HSCT database, and medication charts were used to
collect the following data: age, gender, weight, height, type
of malignancy requiring transplant, date of autologous
HSCT, chemotherapy conditioning regimen, ﬁlgrastim and
antibiotic administration, documented infections, length of
stay, and survival.
Results: There were 79-matched pairs that met inclusion
criteria. The day +5 group had an average time to engraft-
ment of 8.27 days compared to 8.96 days in the day +10
group (p¼0.006). All secondary endpoints were similar
between both groups, including rates of infection and total
febrile days. There was no difference seen with average
length of stay between the two groups (p¼0.745).
Conclusion: The average time to engraftment was
statistically signiﬁcant, in favor of patients who received
ﬁlgrastim earlier in their transplant course on day +5.
However the primary and secondary endpoints results are
not clinically signiﬁcant. Future directions include a cost
analysis to assess economic outcomes.343
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Table I
Etiology of re-admission
Reason for admission Events
Documented infection 95 (34%)
GVHD 58 (21%)
Unexplained fever 58 (21%)
Relapse 29 (10%)
Gastrointestinal symptoms 28 (10%)
Other 8 (2%)
Total events 276
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Background: Although small studies have linked poor
nutritional status pre-hematopoietic stem cell transplant
(HSCT) to metabolic derangements post-HSCT, no large study
has studied the inﬂuence of nutritional support initially after
HSCT on clinical outcomes. We hypothesized that better
enteral (EN) or parenteral nutrition (PN) before and peri-
HSCT would correlate with improved nutritional status and
fewer complications after HSCT including graft-versus-host
disease (GVHD). We conducted a multi-institutional, IRB
approved retrospective study to compare the nutritional
status of patients who received EN, PN, or suboptimal
nutrition in the week before and the ﬁrst 4 weeks post-HSCT
using a novel nutritional summary score.
Method: We devised the nutrition summary score by
assigning a number from 0-2 (0¼no/poor EN/PN, 1¼PN for
goal calories, and 2¼EN for majority of goal) weekly for the 5
weeks (-1, 1, 2, 3, 4) per patient; the scores were summed
(total summary score ranged from 0-10). Nutritional assess-
ments and outcomes were abstracted from medical records
at day 28, day 100, and 1 year after HSCT.
Results: Data were captured from 162 patients (78%
pediatric and 22% adult) from 5 institutions. Patients were a
median age of 10.34 years (range: 1-75), 58% male, and 75%
received myeloablative, 17% reduced intensity, and 8% non-
myeloablative HSCT. At the pre- and peri-HSCT period, few
patients had gastric tubes (6/162) but 44% (72/162) had
nasogastric tubes for EN. Themajority (89%) engrafted by day
+28, and GVHD rates reﬂect the predominance of pediatric
patients with only 14% (22/162) grade I-II acute GVHD
(aGVHD), 17% (27/162) grade III-IV aGVHD, 10% (17/162)
limited chronic, and 10% (16/162) chronic extensive GVHD.
Mean summary nutrition scores and % EN for each time point
were: pre-BMT: 1.42 and 70% EN, week 1: 1.41 and 64%,
week 2: 1.3 and 52%, week 3: 1.3 and 54%, and week 4 1.3 and
58%. The day +28 albumin was correlated directly with the
summary nutrition score (p<0.0001). The weight 100
days after HSCT was also associated with summary
nutritional score (p¼0.017), while chronic extensive GVHD
was associated with lower nutrition score (p¼0.047). Using
only patients who received EN at some point (at least one
value of 2 in the 5 weeks), weight at day 28 (p¼0.002) and
day 100 (p<0.002), and lower risk of cGVHD (p< 0.04) all
were signiﬁcant, suggesting that EN contributed to these
outcomes.
Conclusions: Our data suggest that EN and PN in the pre-
and peri-HSCT period correlate with better nutrition after
HSCT including albumin at day +28 and weight at day +100
and that these may inﬂuence risk for chronic extensive
GVHD, a major complication of HSCT. Further, our data
suggest that EN initially after HSCT may be important,
and support a prospective study to evaluate whether
interventions to improve enteral alimentation enhance
outcomes and diminish the risk of chronic extensive GVHD.344
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Introduction: Hematopoietic stem cell transplantation
(HSCT) provides potential curative treatment for various
benign and malignant conditions. However, there is a high
rate of patients requiring readmission to the hospital within
six months of transplantation. There is only limited literature
evaluating risk factors and causes of readmission of children,
adolescents and young adults (AYA) who underwent HSCT.
Materials and Methods: A retrospective analysis of patients
aged  26 years treated at University of Texas MD Anderson
Cancer Center with HSCT was conducted using descriptive
measures.
Results: A retrospective chart review of 435 transplants in
pediatric and AYA patients from the period of 2008 to 2013
revealed that 161 (37%) patients had at least one hospital
readmission within 180 days of transplant. Ninety-ﬁve
patients were male. The median age at transplant was 21
(range 1-26) years. Primary diagnoses were as follows: he-
matologic malignancy (n¼115), solid tumor (n¼32), and
non-malignant conditions (n¼17). Lansky or Karnofsky
function levels were at a median of 90% at the time of
transplant. Amongst patients readmitted, 87% of patients
received allogeneic HSCT and 13% had autologous HSCT. The
median number of readmissions per patient was 2 (range
1-6). Twenty-nine (18 %) patients were transplanted more
than one time including 4 patient readmits as part of tandem
transplant. Forty-three (29%) patients with solid and
hematological malignancies were not in remission at time of
transplant. A total of 276 readmission events were reported
in the study. The etiology of readmission was multifactorial,
and the event etiologies are summarized in Table I. At a
median follow up of 23.5 months (range 0.2-72), 88 of 161
readmitted patients remain alive. Causes of death were due
to disease recurrence (n¼46) and transplant related
mortality (n¼ 27).
Discussion: This is the largest reported pediatric and young
adult cohort reporting the etiology of readmission within 6
months after HSCT. The highest cause of readmission was
documented infection. Disease relapse contributed to the
high mortality of these patients. We aim to deﬁne a risk
standardized approach to decrease hospital readmissions
post HSCT, identify a low risk group of patients and devise
intervention(s) that reduce the rate of readmissions.345
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